[Form 4] Kura Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Kura Oncology Chief Medical Officer Mollie Leoni received 82,500 shares of common stock upon vesting of performance-based restricted stock units tied to a development milestone achieved on 09/27/2025. Immediately following, 12,314 shares were sold on 09/29/2025 at a price of $8.9422 per share to cover taxes, leaving the reporting person with 158,439 shares beneficially owned. The filing states each PSU converts to one share if performance and service conditions are met; 1/6th of the grant vested when a milestone was met. Transactions were reported on a Form 4 by one reporting person.

Positive

• 82,500 shares vested from performance-based RSUs, indicating achievement of a development milestone
• Post-transaction beneficial ownership remains documented at 158,439 shares, providing transparency

Negative

• Sale of 12,314 shares occurred, reducing immediate insider holdings
• Filing lacks context on total company shares outstanding, so ownership percentage impact is unclear

Insights

Corporate Governance Expert

TL;DR: Insider received vested PSUs and executed a routine sell-to-cover for taxes, reflecting compensation mechanics rather than strategic trading.

The disclosure shows performance-based equity converted to common stock after a specified development milestone was met, with a subsequent technical sale to satisfy tax withholding. This is a common compensation settlement and does not indicate a change in control or material shift in insider stake. Ownership after transactions remains substantial at 158,439 shares, but the filing provides no information on the total outstanding share base to assess percentage ownership.

Securities Analyst

TL;DR: Materiality to investors appears limited; transactions are compensation-driven and routine.

The report quantifies the specific amounts: 82,500 shares vested, 12,314 shares sold at $8.9422 per share to cover taxes, and a post-transaction beneficial ownership of 158,439 shares. These are precise figures useful for monitoring insider holdings, but absent additional context such as total dilution or insider selling patterns, the event is informational rather than market-moving.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Leoni Mollie

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

12730 HIGH BLUFF DRIVE, SUITE 400

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/27/2025		A		82,500	A	$0	170,753	D
Common Stock	09/29/2025		S(1)		12,314	D	$8.9422	158,439	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023 and January 2, 2025. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on September 27, 2025, resulting in the vesting of 1/6th of the underlying shares.

	Thomas Doyle, Attorney-in-fact for Mollie Leoni	09/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions were reported for KURA in this Form 4?

The Chief Medical Officer had 82,500 common shares vest on 09/27/2025 and sold 12,314 shares on 09/29/2025 at $8.9422 per share to cover taxes.

Why were 12,314 shares sold after the PSUs vested?

The filing states the sale was a sell-to-cover transaction to pay taxes associated with the vesting of 1/6th of the underlying PSUs.

How many shares does Mollie Leoni beneficially own after these transactions?

After the reported transactions the filing shows beneficial ownership of 158,439 shares.

What triggered the vesting of the performance-based restricted stock units (PSUs)?

Vesting occurred because a specified development milestone was determined to be met on 09/27/2025, triggering 1/6th of the PSUs to vest.

Do the PSUs convert to common stock on a one-for-one basis?

Yes; the filing states each PSU represents the contingent right to receive one share of common stock upon satisfying performance and service conditions.